Vladimir Cmiljanović

1.2k total citations
15 papers, 794 citations indexed

About

Vladimir Cmiljanović is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Organic Chemistry. According to data from OpenAlex, Vladimir Cmiljanović has authored 15 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 3 papers in Organic Chemistry. Recurrent topics in Vladimir Cmiljanović's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Lymphoma Diagnosis and Treatment (4 papers) and Synthesis and biological activity (2 papers). Vladimir Cmiljanović is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Lymphoma Diagnosis and Treatment (4 papers) and Synthesis and biological activity (2 papers). Vladimir Cmiljanović collaborates with scholars based in Switzerland, Italy and United Kingdom. Vladimir Cmiljanović's co-authors include Matthias P. Wymann, Bernd Giese, Romina Marone, Thomas Bohnacker, Denise Rageot, Doriano Fabbro, Florent Beaufils, Roger Williams, Marketa Zvelebil and Anna Melone and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Vladimir Cmiljanović

14 papers receiving 774 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vladimir Cmiljanović Switzerland 6 614 142 120 119 101 15 794
Thomas Bohnacker Switzerland 16 624 1.0× 177 1.2× 103 0.9× 138 1.2× 198 2.0× 23 889
Martin Pass United Kingdom 16 551 0.9× 212 1.5× 250 2.1× 62 0.5× 69 0.7× 31 873
Lora B. Kramer United States 22 871 1.4× 46 0.3× 298 2.5× 98 0.8× 91 0.9× 34 1.2k
Michele Dowless United States 15 597 1.0× 47 0.3× 280 2.3× 72 0.6× 98 1.0× 26 871
Merav Yoeli-Lerner United States 7 637 1.0× 42 0.3× 182 1.5× 38 0.3× 104 1.0× 7 814
Hong Chang United States 13 463 0.8× 121 0.9× 346 2.9× 37 0.3× 41 0.4× 18 829
Wei Wei Prior United States 8 644 1.0× 53 0.4× 199 1.7× 131 1.1× 49 0.5× 10 888
Jesika S. Faridi United States 11 329 0.5× 39 0.3× 108 0.9× 127 1.1× 38 0.4× 19 536
Lucía Cordeu Spain 18 970 1.6× 241 1.7× 107 0.9× 87 0.7× 85 0.8× 23 1.4k
Ana M. Cosialls Spain 18 601 1.0× 27 0.2× 255 2.1× 178 1.5× 129 1.3× 29 842

Countries citing papers authored by Vladimir Cmiljanović

Since Specialization
Citations

This map shows the geographic impact of Vladimir Cmiljanović's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Cmiljanović with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Cmiljanović more than expected).

Fields of papers citing papers by Vladimir Cmiljanović

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Cmiljanović. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Cmiljanović. The network helps show where Vladimir Cmiljanović may publish in the future.

Co-authorship network of co-authors of Vladimir Cmiljanović

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Cmiljanović. A scholar is included among the top collaborators of Vladimir Cmiljanović based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Cmiljanović. Vladimir Cmiljanović is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cascione, Luciano, Afua A. Mensah, Alberto J. Arribas, et al.. (2025). Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype. Hematological Oncology. 43(2). e70055–e70055. 1 indexed citations
2.
Schön, Jacob, Donata Hoffmann, Nico Joël Halwe, et al.. (2024). High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters. npj Vaccines. 9(1). 206–206. 1 indexed citations
3.
Jankú, Filip, Grace M. Choong, Mateusz Opyrchal, et al.. (2024). A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers. 16(6). 1137–1137. 10 indexed citations
4.
Cascione, Luciano, Chiara Tarantelli, Andrea Rinaldi, et al.. (2021). Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation. Non-Coding RNA. 7(2). 26–26. 3 indexed citations
5.
Tarantelli, Chiara, Eugenio Gaudio, Petra Hillmann, et al.. (2019). The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers. 11(6). 775–775. 12 indexed citations
6.
Bohnacker, Thomas, A.E. Prota, Florent Beaufils, et al.. (2017). Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications. 8(1). 14683–14683. 86 indexed citations
7.
Beaufils, Florent, Vladimir Cmiljanović, Thomas Bohnacker, et al.. (2017). 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry. 60(17). 7524–7538. 115 indexed citations
8.
Hillmann, Petra, Denise Rageot, Florent Beaufils, et al.. (2017). Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530. Cancer Research. 77(13_Supplement). 159–159. 3 indexed citations
9.
Gaudio, Eugenio, Petra Hillmann, Filippo Spriano, et al.. (2016). The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. European Journal of Cancer. 69. S38–S38. 1 indexed citations
10.
Tarantelli, Chiara, Eugenio Gaudio, Ivo Kwee, et al.. (2015). The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. Blood. 126(23). 4005–4005. 1 indexed citations
11.
Cmiljanović, Vladimir, Robert A. Ettlin, Florent Beaufils, et al.. (2015). Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. Cancer Research. 75(15_Supplement). 4514–4514. 3 indexed citations
12.
Tarantelli, Chiara, Eugenio Gaudio, Ivo Kwee, et al.. (2015). Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. Cancer Research. 75(15_Supplement). 2652–2652.
13.
14.
Marone, Romina, Thomas Bohnacker, Christian Schnell, et al.. (2009). Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Molecular Cancer Research. 7(4). 601–613. 92 indexed citations
15.
Marone, Romina, Vladimir Cmiljanović, Bernd Giese, & Matthias P. Wymann. (2007). Targeting phosphoinositide 3-kinase—Moving towards therapy. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1784(1). 159–185. 465 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Bohnacker Breakdown of academic impact, for papers by Martin Pass Breakdown of academic impact, for papers by Lora B. Kramer Breakdown of academic impact, for papers by Michele Dowless Breakdown of academic impact, for papers by Merav Yoeli-Lerner Breakdown of academic impact, for papers by Hong Chang Breakdown of academic impact, for papers by Wei Wei Prior Breakdown of academic impact, for papers by Jesika S. Faridi Breakdown of academic impact, for papers by Lucía Cordeu Breakdown of academic impact, for papers by Ana M. Cosialls
Rankless by CCL
2026